Spleen tyrosine kinase (Syk) as a therapeutic target in antibody-dependent transplant rejection.

脾酪氨酸激酶 (Syk) 作为抗体依赖性移植排斥的治疗靶点。

• 批准号: nhmrc : 1057565
• 负责人: A/Pr David Nikolic-Paterson
• 金额: $ 41.74万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/spleen-tyrosine-kinase-transplant-rejection/454619
• 关键词: Spleen; tyrosine; kinase; Syk; therapeutic

While kidney transplantation is a life saving treatment for those with end-stage kidney failure, a significant number of patients face long waits on dialysis because they have antibodies that would cause rejection of most potential donor kidneys. This project seeks to address this problem using a new strategy to treat antibody-mediated rejection and thereby enable such patients to receive a transplant without the fear of severe rejection.

虽然肾移植对于终末期肾衰竭患者来说是一种挽救生命的治疗方法，但相当多的患者面临着漫长的透析等待，因为他们的抗体可能会导致大多数潜在的供者肾脏发生排斥反应。该项目试图通过一种新的策略来解决这一问题，以治疗抗体介导的排斥反应，从而使这些患者能够接受移植，而无需担心严重的排斥反应。